keyword
https://read.qxmd.com/read/38537431/maintenance-treatment-of-pemphigus-with-rituximab-in-real-life-a-single-center-study-of-50-patients
#21
JOURNAL ARTICLE
A Louchez, T El Aarbaoui, A Weill, O Gaudin, L Jelti, T Belmondo, P Wolkenstein, S Ingen-Housz-Oro
BACKGROUND: Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients. PATIENTS AND METHODS: Our single-center retrospective study included all patients with pemphigus diagnosed between 01/2015 and 10/2020 and receiving at least one initial infusion of RTX...
March 25, 2024: Annales de Dermatologie et de Vénéréologie
https://read.qxmd.com/read/38534263/claudin-4-upregulation-in-acantholytic-and-autoimmune-mediated-bullous-disorders
#22
JOURNAL ARTICLE
Chau M Bui, Huy G Vuong, Minh-Khang Le, Kristin J Rybski, Hatice B Zengin, Haiming Tang, Bruce R Smoller
Claudin-4 is a key component of tight junctions, which play an important role in the formation of the epidermal barrier by forming a circumferential network in the granular layer that serves as a gatekeeper of the paracellular pathway. The aim of this study is to illustrate claudin-4 immunohistochemical staining patterns of different blistering disorders. We collected 35 cases, including two Hailey-Hailey disease, one Darier disease, three Grover disease, one acantholytic acanthoma, two warty dyskeratoma, 11 pemphigus vulgaris (PV) including six mucosal PV, and two pemphigus foliaceus...
December 21, 2023: Dermatopathology (Basel, Switzerland)
https://read.qxmd.com/read/38532568/alterations-of-circulating-free-fatty-acids-in-patients-with-pemphigus-vulgaris
#23
JOURNAL ARTICLE
Roberto Maglie, Simone Baldi, Giulia Nannini, Leandro Di Gloria, Marco Pallecchi, Gianluca Bartolucci, Matteo Ramazzotti, Elena Niccolai, Maria Efenesia Baffa, Biagioni Camilla, Farzan Solimani, Emiliano Antiga, Amedeo Amedei
Free fatty acids (FFA) have gained research interest owing to their functions in both local and systemic immune regulation. Changes in the serum levels of anti-inflammatory short chain fatty acids (SCFA), primarily derived from the gut microbiota, and pro-inflammatory medium (MCFA) and long (LCFA) chain fatty acids, derived from either the gut microbiota or the diet, have been associated with autoimmunity. Circulating FFA were retrospectively analysed by a gas chromatography-mass spectrometry method in the serum of 18 patients with pemphigus vulgaris (PV) at the baseline and 6 months (n = 10) after immunosuppressive treatments, and 18 healthy controls (HC)...
March 2024: Experimental Dermatology
https://read.qxmd.com/read/38524019/the-prevalence-of-clinically-undiagnosed-depression-in-patients-with-autoimmune-bullous-diseases-seen-at-inkosi-albert-luthuli-central-hospital-durban-south-africa
#24
JOURNAL ARTICLE
Nkosiyenzile Cele, Josiah T Masuka, Khumo Duze, Anisa Mosam
Background Chronic autoimmune bullous diseases have been associated with major depression in previous studies. This has been attributed to inflammatory cytokines, chronic pain, and the chronicity and debilitating nature of the disease. As no similar studies have been conducted in our setting, we aimed to determine the prevalence and severity of clinically undiagnosed depression in patients with autoimmune bullous diseases. Methodology We performed a cross-sectional study among outpatients managed in a bullous disease clinic at Inkosi Albert Luthuli Central Hospital, a quaternary provincial hospital in Durban, South Africa...
February 2024: Curēus
https://read.qxmd.com/read/38505433/beyond-the-surface-a-clinical-insight-into-a-60-year-old-male-with-pemphigus-vulgaris
#25
Miis Akel, Maggie Wright, Bialo Aladum, Sergio Hernandez Borges
Pemphigus vulgaris, a rare and life-threatening autoimmune disorder, presents with painful skin and mucosal lesions, leading to blistering sores attributed to acantholysis. This study delves into the clinical manifestations, risk factors, and diagnostic intricacies associated with pemphigus vulgaris, with a focus on a representative case highlighting the challenges in its recognition and management. We explore the case of a 60-year-old male with pemphigus vulgaris, whose initial presentation involved yellow-crusting lesions on the scalp progressing to non-pruritic lesions on the chest, neck, and inguinal areas...
February 2024: Curēus
https://read.qxmd.com/read/38504438/beyond-the-skin-b-cells-in-pemphigus-vulgaris-tolerance-and-treatment
#26
JOURNAL ARTICLE
Anne-Lise Strandmoe, Jeroen Bremer, Gilles F H Diercks, Antoni Gostyński, Emanuele Ammatuna, Hendri H Pas, Marjan Wouthuyzen-Bakker, Gerwin A Huls, Peter Heeringa, Jon D Laman, Barbara Horváth
Pemphigus vulgaris is a rare autoimmune bullous disease characterized by blistering of the skin and mucosa owing to the presence of autoantibodies against the desmosome proteins desmoglein 3 and occasionally in conjunction with desmoglein 1. Fundamental research into the pathogenesis of PV has revolutionized its treatment and outcome with rituximab, a B-cell-depleting therapy. The critical contribution of B cells to the pathogenesis of pemphigus is well accepted. However, the exact pathomechanism, mechanisms of onset, disease course, and relapse remain unclear...
March 20, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38493933/efficacy-and-safety-of-rilzabrutinib-in-pemphigus-pegasus-phase-3-randomized-study
#27
JOURNAL ARTICLE
Dedee F Murrell, Frédéric Caux, Aikaterini Patsatsi, Owen Hagino, Lidia Rudnicka, Snejina Vassileva, Soner Uzun, Jenny Ye, Karl Yen, Puneet Arora, Steven G Gourlay, Pascal Joly, Victoria P Werth
TRIAL DESIGN: Pemphigus is a rare, but life-threatening autoimmune disease requiring long-term treatment that minimizes corticosteroid (CS) exposure while providing consistent disease control. The phase 2 pemphigus study of oral, reversible, covalent Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib demonstrated rapid and sustained efficacy with well-tolerated safety. METHODS: Adults (18-80 y) were randomized 1:1 to rilzabrutinib 400 mg (n=65) or placebo (n=66) twice daily (with CS ≤0...
March 15, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38490369/diagnostic-utility-of-gingival-biopsy-for-pemphigus-vulgaris-and-mucosa-membrane-pemphigoid-a-10-year-cohort-study
#28
JOURNAL ARTICLE
Junjiang Liu, Can Hu, Jing He, Jingtian Mu, Shimeng Wang, Qi Han, Jia Li, Mei Lin, Qinghong Gao, Fanglong Wu, Hongmei Zhou
No abstract text is available yet for this article.
March 13, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38487393/regenerative-potential-of-platelet-concentrates-in-chronic-oral-mucosal-lesions
#29
JOURNAL ARTICLE
Abdel-Hameed Hijazi, Faez Saleh Al-Hamed, Faleh Tamimi, Sadeq A Al-Maweri, Nader Hamdan, David J Psutka, Peter Ta, Hagen Klieb
Chronic oral mucosal diseases (COMDs) represent a significant challenge for clinicians and patients. They are commonly associated with chronic pain and negative effects on healing and patient's quality of life. Regenerative medicine including the use of biological autologous blood-derived substances (e.g., platelet concentrates [PCs]), has been reported to improve healing and reduce pain in orthopedic and maxillofacial surgeries as well as chronic oral mucosal diseases. In this review, we aim to describe the different types of PCs and their applications in the management of COMDs such as lichen planus, mucositis, pemphigus vulgaris, mucous membrane pemphigoid, and plasma cell mucositis, in terms of healing potential, pain control, and quality of life...
2024: Journal of Oral Biology and Craniofacial Research
https://read.qxmd.com/read/38482465/autoreactive-antibodies-associated-with-castleman-disease-triad
#30
Jacqueline A Turner, Ali Hakimi, Hannah Lee, Jeffrey T Schowinsky, Jeffrey M Sippel, Bradford J Siegele, Raul M Torres, William A Robinson
The Castleman triad has been described in a select few patients presenting with a retroperitoneal mass, mucocutaneous pemphigus vulgaris, and bronchiolitis obliterans. Here, we describe the Castleman triad in a 19-year-old male with unicentric hyaline vascular type Castleman disease (HV-CD). This patient presented with an array of positive antibodies, including anti-cyclic citrullinated peptide, anti-double-stranded DNA, and Sjogren's IgG. Interestingly, the patient's rheumatologic symptoms resolved after tumor resection, while his antibody profile remained relatively unchanged...
2024: Case Reports in Immunology
https://read.qxmd.com/read/38482134/a-comprehensive-review-of-oral-microenvironment-changes-and-orofacial-adverse-reactions-after-covid-19-vaccination-the-good-the-bad-and-the-ugly
#31
JOURNAL ARTICLE
Shaghayegh Najary, Mohammadreza Vatankhah, Gita Khadivi, Seyyede N Salehi, Mohammad A K Tabari, Noosha Samieefar, Mohammad Behnaz
BACKGROUND AND AIMS: Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have the potential to alter several biological systems concurrently with remolding the immune system, most of which are related to immunization, while some others are known as adverse effects. This review aims to explore the potential effects of vaccination on the oral microenvironment and classifies them as good, bad, or ugly, with a brief review of facial diseases following coronavirus disease 2019 (COVID-19) vaccination...
March 2024: Health Science Reports
https://read.qxmd.com/read/38465545/differences-among-indian-and-european-pemphigus-patients-based-on-demographics-clinical-parameters-and-propensity-for-relapse-results-of-a-prospective-bicontinental-cohort-study
#32
JOURNAL ARTICLE
Dipankar De, Shilpa Shilpa, Sheetanshu Kumar, Kossara Drenovska, Hitaishi Mehta, Nina van Beek, Naresh Sachdeva, Alexandra Fleva, Martin Shahid, Sanjeev Handa, Anastasia Giannakou, Elissaveta Naumova, Rahul Mahajan, Aikaterini Kyriakou, Spaska Lesichkova, Elisabeth Lazaridou, Bishan Dass Radotra, Kamal Kishore, Enno Schmidt, Snejina Vassileva, Aikaterini Patsatsi
Limited studies have explored pemphigus variations among different ethnic groups residing in their respective geographical locations. This bicontinental study aimed to compare clinical and immunological parameters in Indian and European pemphigus patients in complete remission, off therapy, or on minimal therapy. 105 patients (India, n= 75; Bulgaria, n=15; Greece, n=15) with pemphigus vulgaris (PV) or pemphigus foliaceous (PF) in complete remission on minimal therapy (n=64) or complete remission off therapy (n=41) were recruited...
December 1, 2023: European Journal of Dermatology: EJD
https://read.qxmd.com/read/38464573/rituximab-induced-psoriasis-in-a-patient-with-pemphigus-vulgaris-a-case-report-and-literature-review
#33
Leila Ghadirzade Arani, Shima Moslemi Haghighi, Soheila Nasiri, Sahar Dadkhahfar
KEY CLINICAL MESSAGE: Rituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management. ABSTRACT: Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38449993/atypical-presentation-of-pemphigus-vulgaris-nail-involvement-in-a-20-year-old-male
#34
Apostolos Katsiaunis, Shari R Lipner
Pemphigus vulgaris (PV) mainly causes blistering of the skin and mucous membranes, with nail unit involvement being rare. Nail involvement may serve as an indicator of disease severity. We present a case of a 20-year-old male with PV who had both cutaneous and nail findings, with nail changes corresponding with disease severity. The patient with biopsy-confirmed PV, on prednisone and mycophenolate, presented to the emergency department with an acute flare of PV and severe mandibular pain and lymphadenopathy...
February 2024: Curēus
https://read.qxmd.com/read/38443120/pemphigus-vulgaris-successfully-treated-with-bromocriptine
#35
JOURNAL ARTICLE
Natalya Lyadova, Narmin S Ghalichi
Pemphigus vulgaris (PV) is an autoimmune blistering skin condition primarily treated with immunosuppressive agents. We describe a case of PV successfully treated with nonconventional treatment, bromocriptine mesylate. Bromocriptine has been used in human trials showing beneficial therapeutic effects in managing autoimmune conditions. The results from experimental trials and the low toxicity of bromocriptine in comparison with immunosuppressive agents form a solid rationale for investigating its role in controlling PV...
March 1, 2024: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/38439728/sars-cov-2-infection-in-pemphigus-vulgaris-two-weeks-after-rituximab-therapy-with-total-recovery-a-case-report
#36
JOURNAL ARTICLE
Lili Róbert, Anikó Kovács, Miklós Sárdy, Melinda Fábián
The mortality risk factors for Corona Virus Disease-19 (COVID-19) infection (caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)) include advanced age, male sex, certain comorbidities, and immunosuppression (1). Pemphigus vulgaris is a rare mucocutaneous autoimmune disease with autoantibodies against desmosomal desmoglein-1 and desmoglein-3, resulting in acantholysis and blister formation. This epithelial barrier defect increases susceptibility to infections, which may lead to relapses (2)...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38431095/disease-severity-and-hospitalization-risk-factors-in-a-cohort-of-hispanic-latino-pemphigus-patients-a-descriptive-retrospective-chart-review
#37
JOURNAL ARTICLE
Rebecca Leibowitz, Mason Seely, Larissa Rodriguez Holms, Danielle Mustin, Robyn Guo, Ron J Feldman, Anne L Marano
No abstract text is available yet for this article.
February 29, 2024: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38427745/direct-immunofluorescence-dif-versus-immunohistochemical-ihc-staining-of-complements-and-immunoglobulins-ig-in-pemphigus-group
#38
JOURNAL ARTICLE
Deepika Rana, Nita Khurana, Shramana Mandal, Bijay Laxmi Sahoo
INTRODUCTION: Pemphigus is a group of bullous disorders of the skin characterized by the formation of autoantibodies present in the intercellular junction of the epidermis. Diagnosis is made by clinical, histopathological examination, and DIF. As DIF needs frozen sections, fluorescent tagged antibodies, UV light microscope for examination, and trained personnel, its non-availability makes a definitive diagnosis challenging. AIMS AND OBJECTIVES: To evaluate the utility of IHC staining of complements and Ig in cases of Pemphigus...
February 19, 2024: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38426103/from-neglect-to-spotlight-the-underappreciated-role-of-b-cells-in-cutaneous-inflammatory-diseases
#39
REVIEW
Eun-Gang Lee, Ji Eun Oh
The skin, covering our entire body as its largest organ, manifests enormous complexities and a profound interplay of systemic and local responses. In this heterogeneous domain, B cells were considered strangers. Yet, recent studies have highlighted their existence in the skin and their distinct role in modulating cutaneous immunity across various immune contexts. Accumulating evidence is progressively shedding light on the significance of B cells in maintaining skin health and in skin disorders. Herein, we integrate current insights on the systemic and local contributions of B cells in three prevalent inflammatory skin conditions: Pemphigus Vulgaris (PV), Systemic Lupus Erythematosus (SLE), and Atopic Dermatitis (AD), underscoring the previously underappreciated importance of B cells within skin immunity...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38416427/evaluation-of-the-status-of-patients-with-autoimmune-bullous-diseases-pemphigus-and-bullous-pemphigoids-in-dermatology-clinics-of-mashhad-university-of-medical-sciences-during-the-covid-19-pandemic-using-telemedicine
#40
JOURNAL ARTICLE
Zohreh Mehri, Yalda Nahidi, Behrokh Ramezani, Shatila Torabi
Background: The COVID-19 pandemic impacted the growth of telemedicine. The challenge was in the way of dermatologists, who needed a comprehensive examination of the lesions. Here, we tried a tele-management of patients with autoimmune bullous diseases. Methods: This cross-sectional study was conducted on confirmed bullous disorder cases. Demographic data and the status of COVID-19 infection were assessed in the patients. Some of the cases were provided online, and some with office visits. Drug and treatment plan changes were compared between these two groups...
February 27, 2024: Telemedicine Journal and E-health
keyword
keyword
40299
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.